Back to News
Market Impact: 0.08
Amino Minder Brings Real Pharmacokinetic Modeling to Peptide and GLP-1 Tracking, Now Live on the Web -- Android App Coming Soon
Source: PR Newswire
Product LaunchesHealthcare & BiotechTechnology & Innovation
Baya Lobo LLC launched Amino Minder, a web-based tracker for peptide and GLP-1 use that extends beyond dose logging to estimate plasma levels over time and model downstream hormone cascades for GH-secretagogue stacks. The announcement provides no revenue, user-growth, pricing, clinical-validation, or financial guidance metrics, limiting expected market relevance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Elon Musk’s dangerous grip on outer space
- J&J prostate cancer drug shows promising tumor responses in early trial
- AI agents could disrupt bank deposits. Why Wall Street may be overreacting
- Ukraine Says Restrictions on Starlink Speed Have Been Lifted